Press Releases MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients at the ASH 2018 Annual Meeting Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…nboutaouiDecember 2, 2018
Press Releases MaaT Pharma to Present Positive Results from Phase 1b/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…MaaT PharmaNovember 6, 2018
Press Releases MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD Microbiome restoration biological drug product to be tested for safety and overall survival impact in…MaaT PharmaOctober 12, 2018
Press Releases MaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…MaaT PharmaSeptember 18, 2018
Press Releases MaaT Pharma and Lutech Sign Licensing Agreement for Graft-vs-Host Disease MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…MaaT PharmaJune 21, 2018
Press Releases Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work Created in the…MaaT PharmaMay 18, 2018
Press Releases MaaT Pharma Launches European Clinical Trial in Acute Graft-versus-Host Disease MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…MaaT PharmaMarch 5, 2018